• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    2 Contact Hour(s)

    Release Date

    Tuesday, August 13, 2019

    Offline Date

    Friday, August 13, 2021

    ACPE Expiration Date

    Sunday, February 13, 2022

    Target Audience

    Pharmacist, Pharmacy Technician, Nurse

    Cost

    $8.00

    • Overview

      Patients with diabetes are also much more likely to suffer from cardiovascular disease than those without diabetes. In fact, cardiovascular disease is the leading cause of death associated with diabetes – certainly a medical double jeopardy. The American Diabetes Association’s (ADA) recently published the 2017 Standards of Medical Care in Diabetes and included new recommendations on treating both diabetes and cardiovascular disease. Pharmacists are often the medical professional that patients reach out to for guidance and explanation on new pharmaco-therapy and individualized treatment. This program will review the ADA’s latest update to the Standards of Medical Care in Diabetes, review recent outcomes trials of antihyperglycemic therapies in patients with type 2 diabetes (T2D) and outline evidence based treatment strategies to mitigate the risk of cardiovascular disease in patients with T2D. 

      Handouts

      • Slide Document :   18265L01_2pp.pdf
      • Slide Document :   18265L01_6pp.pdf

      Financial Support By

      PharmCon
    • Pharmacist

      Recognize the drug therapies and show evidence of benefit in improving blood sugars and decreasing risk of cardiovascular and renal events
      Summarize the ADA and AACE guidelines with respect to efficacy and safety particularly when analyzing cardiovascular and renal outcomes
      Identify guidelines that are recommended by the ADA and AACE for CV risk reduction and the others in this class

      Pharmacy Technician

      Review how different treatment options work to lower blood sugar levels in patients with diabetes
      Recognize the effects of diabetes agents on glycosylated hemoglobin levels (A1c)
      List some common safety concerns about different agents used to treat type 2 diabetes

      Nurse

      Identify guidelines that are recommended by the ADA and AACE for CV risk reduction and the others in this class
      Recognize the drug therapies and show evidence of benefit in improving blood sugars and decreasing risk of cardiovascular and renal events
      Summarize the ADA and AACE guidelines with respect to efficacy and safety particularly when analyzing cardiovascular and renal outcomes
    • Activity Type

      Knowledge

      CE Broker

      20-644283

      Universal Activity Number

      Pharmacist 0798-0000-18-265-H01-P
      Pharmacy Technician 0798-0000-18-265-H01-T
      Nurse 0798-0000-18-265-H01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

    • Faculty

      Tamara  Goldberg, PharmD, BCPS
      Associate Professor of Pharmacy Practice, Arnold & Marie Schwartz College of Pharmacy and Health Sciences Long Island University

    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).